• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.

作者信息

Zanchetta J R, Bogado C E

机构信息

Instituto de Investigaciones Metabolicas and USAL University School of Medicine, Buenos Aires, Argentina.

出版信息

J Bone Miner Res. 2001 Jan;16(1):189-90. doi: 10.1359/jbmr.2001.16.1.189.

DOI:10.1359/jbmr.2001.16.1.189
PMID:11149484
Abstract
摘要

相似文献

1
Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.雷洛昔芬可逆转轻度无症状原发性甲状旁腺功能亢进绝经后女性的骨质流失。
J Bone Miner Res. 2001 Jan;16(1):189-90. doi: 10.1359/jbmr.2001.16.1.189.
2
The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.雷洛昔芬对居住在长期护理机构中的老年女性骨转换标志物的影响。
J Am Geriatr Soc. 2004 May;52(5):779-83. doi: 10.1111/j.1532-5415.2004.52218.x.
3
Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.雷洛昔芬可改善原发性胆汁性肝硬化骨质疏松女性的骨量：一项试点研究的结果。
Liver Int. 2005 Feb;25(1):117-21. doi: 10.1111/j.1478-3231.2005.01026.x.
4
Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.选择性雌激素受体调节剂（盐酸雷洛昔芬）对绝经后骨质疏松症治疗中白细胞介素-6、肿瘤坏死因子-α、转化生长因子-β1及骨转换标志物的影响
Eur Cytokine Netw. 2007 Sep;18(3):148-53. doi: 10.1684/ecn.2007.0097. Epub 2007 Sep 7.
5
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.雷洛昔芬治疗下骨矿物质密度与椎体骨折发生风险之间的关系。
J Bone Miner Res. 2002 Jan;17(1):1-10. doi: 10.1359/jbmr.2002.17.1.1.
6
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.与雷洛昔芬相比，来索昔芬治疗绝经后女性预防骨质流失的效果。
Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f.
7
Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.低骨量或骨质疏松绝经后妇女的骨量、浸润性乳腺癌发病率与雷洛昔芬治疗之间的关系
Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.
8
[Osteoporosis therapy compared. More solid bones with bisphosphonates].[骨质疏松症治疗对比。双膦酸盐使骨骼更强健]
MMW Fortschr Med. 2003 Aug 7;145(31-32):55.
9
[SERM and quality of bone].[选择性雌激素受体调节剂与骨质量]
Clin Calcium. 2004 Oct;14(10):96-9.
10
[Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].[定义雷洛昔芬作为绝经后骨质疏松症治疗药物的作用：聚焦其药理特性]
Clin Calcium. 2004 Oct;14(10):73-80.

引用本文的文献

1
Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.再探甲状旁腺疾病中的骨：来自流行病学、手术及新药疗效的证据
Endocr Rev. 2025 Jul 15;46(4):576-620. doi: 10.1210/endrev/bnaf010.
2
Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management.原发性甲状旁腺功能亢进症：诊断与药物治疗的叙述性综述
J Clin Med. 2021 Apr 9;10(8):1604. doi: 10.3390/jcm10081604.
3
Recent Advances on Magnetic Sensitive Hydrogels in Tissue Engineering.组织工程中磁敏水凝胶的最新进展
Front Chem. 2020 Mar 6;8:124. doi: 10.3389/fchem.2020.00124. eCollection 2020.
4
Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.雷洛昔芬可改善慢性囊性肾病动物模型的骨骼特性。
Kidney Int. 2016 Jan;89(1):95-104. doi: 10.1038/ki.2015.315. Epub 2016 Jan 4.
5
Strategies to improve physical activity by exercise training in patients with chronic kidney disease.通过运动训练改善慢性肾病患者身体活动的策略。
Int J Nephrol Renovasc Dis. 2015 Mar 10;8:19-24. doi: 10.2147/IJNRD.S65702. eCollection 2015.
6
Therapy for patients with CKD and low bone mineral density.慢性肾脏病及低骨密度患者的治疗。
Nat Rev Nephrol. 2013 Nov;9(11):681-92. doi: 10.1038/nrneph.2013.182. Epub 2013 Oct 8.
7
Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.阿仑膦酸钠与雷洛昔芬治疗原发性甲状旁腺功能亢进症的比较。
J Endocrinol Invest. 2013 Dec;36(11):1076-82. doi: 10.3275/9095. Epub 2013 Sep 27.
8
Bone turnover markers in primary hyperparathyroidism.原发性甲状旁腺功能亢进症中的骨转换标志物。
J Clin Densitom. 2013 Jan-Mar;16(1):22-7. doi: 10.1016/j.jocd.2012.11.004.
9
Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.西那卡塞作为原发性甲状旁腺功能亢进症的替代治疗：成就与展望。
Endocrine. 2011 Jun;39(3):199-204. doi: 10.1007/s12020-011-9452-7. Epub 2011 Mar 26.
10
Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.西那卡塞可降低难治性原发性甲状旁腺功能亢进患者的血清钙浓度。
J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72. doi: 10.1210/jc.2008-2640. Epub 2009 May 26.